C-BIOMEX
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
C-BIOMEX - overview
Established
2017
Location
-, -, South Korea
Primary Industry
Biotechnology
About
Based in Gyeongsangbuk-do, South Korea, and founded in 2017, Cbiomex Inc. also known as C-BIOMEX operates as a biopharmaceutical company that is focused on the development of peptide therapeutics. In June 2022, the firm raised KRW 6. 5 billion in series B funding led by investors E&Venture Partners, Enlight Ventures, Mirae Asset Venture Investment, and Stassets Investment.
Along with the participation of Innopolis Partners and SHIN POONG PHARM. CO. , LTD. The firm as of April 2023, is led by its CEO, Cha Junhoe.
The company develops theragnostic technology for peptide radioactive treatment and diagnosis for cancer. Through its platform, CUS™, the company is working on radioactive isotopes for cancer cells, based on preclinical data to screen peptides that selectively bind to target substances. Their peptides are designed to have higher stability in blood and greater binding ability and selectivity to target substances, making them more effective than existing drugs. The projects in C-Biomex’s pipeline, as of April 2023, are CBT-001, for kidney cancer, is in late discovery, and CBT-002, for neuroendocrine tumor, CBT-004, for solid cancer, and CBT-005, for achondroplasia, are in early discovery stage.
The company plans to its June 2022 funding to launch the phase 1 clinical IND of CBT-001.
Current Investors
Innopolis Partners, Mirae Asset Venture Investment, Enlight Ventures
Primary Industry
Biotechnology
Sub Industries
Molecular Science, Genetics & Gene Therapy, Biopharmaceuticals
Website
https://cbiomex.com/
Company Stage
Series B
Total Amount Raised
Subscriber access only
C-BIOMEX - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.